06.01.2014 - The Johnson & Johnson company tested a vaccine against Ebola

US corporation Johnson & Johnson announced the testing of a vaccine against Ebola virus on humans. According to the company, which, together with the Danish Bavarian Nordic plans before the end of the month to complete testing, in April on the market may appear 400 thousand doses of vaccine. According to forecasts, this year will be able to produce 2 million doses of the drug with a possible increase in production capacity to 5 million doses. Due to this news, we expect the stock price increase, but the effect will be short-term in connection with a broad diversification of the company's business and a relatively low portion of the revenues from the sale of the vaccine. According to our estimates the company's shares may decrease by 10-15% in the medium term.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.